Featured Products related products

Structure Cat No. Product Name CAS No. Product description
V39377 DBCO-PEG3-TCO DBCO-PEG3-TCO is a non-cleavable (non-degradable) ADC linker containing 3 Polyethylene glycol (PEG) units, which may be utilized to prepare Antibody-drug conjugates (ADC).
V32889 DPN 1428-67-7 DPN (Diarylpropionitrile) is a non-steroidal estrogen receptor ERβ selective ligand with EC50 of 0.85 nM.
V0630 Pexidartinib (PLX3397; Turalio; CML261; FP113) 1029044-16-3 Pexidartinib (formerly PLX-3397; CML-261;FP-113; trade name Turalio) is an orally bioavailable and multi-targeted RTK (receptor tyrosine kinase) inhibitor of CSF-1R, Kit, and Flt3 with potential antineoplastic activity.
V19288 DCKA 131123-76-7 5,7-Dichlorokynurenic acid (5,7-DCKA) is a selective NMDA receptor glycine site competitive antagonist (inhibitor) with a Kb of 65 nM.
V47750 15-Nor-14-oxolabda-8(17),12E-Diene-18-oic acid 1039673-32-9 15-Nor-14-oxolabda-8(17),12E-Diene-18-oic acid (compound 9) is a compound extracted from Chloranthus spicatus.
V30349 Echinocystic acid 510-30-5 Echinocystic acid is a naturally occurringpentacyclic triterpene found in the fruits of Gleditsia sinensis Lam with antioxidant, anti-inflammatory and anticancer pactivities.
V20571 Enmenol 28957-06-4 Enmenol is a novel and potent bioactive compound
V0342 Tofacitinib (CP690550; tasocitinib) 477600-75-2 Tofacitinib (also known as tasocitinib or CP-690550, sold under the brandXeljanz),is a novel and potent inhibitor of JAK3 (Janus-Associated kinase) with potential anti-inflammatory activity.
V0390 EPZ015666 (GSK3235025) 1616391-65-1 EPZ015666 (GSK-3235025), an analog ofEPZ-015866, is a potent, selective and orally bioavailable inhibitor of PRMT5 (protein arginine methyltransferase) with antineoplastic activity.
V52787 Carbazole-d8 (咔唑-d8) 38537-24-5 Carbazole-d8 is the deuterated form of Carbazole (HY-D0204).
V0415 Apabetalone (RVX-08, RVX-000222) 1044870-39-4 Apabetalone (also known as RVX-208, RVX000222) is a novel and potent inhibitor of BET (Bromodomain and Extra-Terminal) bromodomain (BD) with potential anti-inflammatory activity and the potential to be used in the treatment of cardiovascular diseases.
V35046 Ditiocarb (Diethyldithiocarbamic acid) 147-84-2 Ditiocarb (Diethyldithiocarbamic acid) is a copper reagent that reacts with Cu2+ solution to form a complex, which increases the copper replacement precipitation rate.
V0245 Acadesine (AICAR; NSC-105823) 2627-69-2 Acadesine (also known as NSC105823,AICA-riboside, and AICAR) is a novel and potent AMPK (AMP-activated protein kinase) activatorwith potential antitumor and antidiabetic activity.
V0729 Ritonavir (ABT-538; Norvir) 155213-67-5 Ritonavir (previously known as ABT-538; A-84538; RTV; ABT538, trade name: Norvir) is a L-valine derivative and potent inhibitor of HIV-1 protease used to treat HIV infection and AIDS. It is widely used as a booster for other protease inhibitors/PIs such as lopinavir, and makes them work better.
V0633 GW2580 (SC203877) 870483-87-7 GW2580 (also known as SC-203877)is a novel, potent, selective, and orally bioavailable c-Fms kinaseCSF-1R inhibitor with potential antineoplastic activity.
V0572 Imatinib Mesylate (STI571; Gleevec; Glivec) 220127-57-1 Imatinib Mesylate (also known as STI571 mesylate; trade names: Gleevec or Glivec), the mesylate salt of imatinib, is an orally bioavailable,potent,multi-kinase inhibitor of v-Abl, c-Kit and PDGFR with potential antitumor activity.
V2967 PF-05089771 1235403-62-9 PF-05089771 (PF05089771) is a potent and subtype selective NaV1.7 inhibitor (IC50 = 11 nM) and Nav1.8voltage-gated sodium channelblocker with the potential to be used in the treatment of chronic neuropathic pain.
V0035 Pomalidomide (CC4047 or actimid) 19171-19-8 Pomalidomide (formerly also known as CC-4047 or actimid), an analog of thalidomide, is a potent andorally bioavailable immunomodulatory molecule with antineoplastic activity.
V0411 (+)-JQ1 1268524-70-4 (+)-JQ1 is a novel, potent and highly specific BET (Bromodomain and extra terminal domain) bromodomain inhibitor with antineoplastic activity.
V0284 Sodium Phenylbutyrate (4-PBA sodium) 1716-12-7 Sodium phenylbutyrate (4-Phenylbutyric acid sodium; 4-PBA sodium),an orphan drug marketed by Ucyclyd Pharma, is a novel and potent histone deacetylase (HDAC) inhibitor used as an as adjunctive therapy for chronic treatment of urea cycle disorders involving deficiencies of argininosuccinic acid synthetase (AS), ornithine transcarbamylase (OTC), or carbamylphosphate synthetase (CPS).
Contact Us Back to top